Ovarian Cancer Research Foundation pledges more than $1 million for research

Health Industry Hub | August 20, 2021 |
[Total: 2    Average: 4.5/5]

Medical News: Two of Australia’s leading researchers in the fight against ovarian cancer have been awarded more than $1 million by the Ovarian Cancer Research Foundation (OCRF) for projects on early detection and effective treatment combinations.

The OCRF has awarded University of Newcastle Professor Pradeep Tanwar $596,000 for a project working to develop a blood test for early detection of ovarian cancer. QIMR Berghofer Medical Research Institute Associate Professor Stacey Edwards has been awarded up to $495,000 to investigate the effectiveness of different treatment combinations.

OCRF CEO Lucinda Nolan said “The OCRF has the expertise to identify ovarian cancer research projects that will have the greatest impact on the largest number of women and girls.

“Since 2001, we have allocated more than $18 million into funding research into ovarian cancer – the most lethal female cancer – to improve lives today and save lives tomorrow.”

Professor Tanwar’s project is working to develop a novel biomarker into a blood test to detect ovarian cancer in its earliest stages. A previous OCRF-supported project allowing Professor Tanwar to collect tissue samples from women with a family history of ovarian cancer enabled his team to uncover a promising blood-based biomarker and test it on 30 women with a family history of ovarian cancer. His team will now conduct tests on 2,000 women, half of whom have invasive or borderline ovarian cancer, and half who do not. This will determine whether the test can achieve the specificity and sensitivity required in a larger cohort of women.

Ms Nolan said an accurate early detection test could save 8000 Australian women over a decade.

“There is no early detection test for ovarian cancer. A cervical screening test (Pap smear) does not detect ovarian cancer,” she said.

“Every day we go without ovarian cancer screening is a day too late.

“The OCRF is Australia’s largest funder of early detection research, and we will continue to fund various research projects with different approaches until we get an effective test that can be applied population-wide.”

Associate Professor Edwards is focused on finding new and more effective treatments for ovarian cancer that also manage recurrence of the disease. This project focuses on the most common and most aggressive type of the disease. If successful, this will be the first study to identify all molecules involved in drug resistance and assess the way they function in tumours. These results will provide evidence that combined therapies could make initial treatment of patients more effective and reduce recurrence of ovarian cancer.

Ms Nolan said “While early detection is important in saving lives, once the cancer is detected it is vital to have new and effective treatments.

“The same ovarian cancer drugs have been used since 1992. A lack of focus on personalised treatment means many women and girls suffer needlessly.”

Further to the funding announcement, the OCRF has also committed to closely collaborating with two project teams from the universities of South Australia and Queensland.

  • University of South Australia Professor Elina Hypponen is working to determine the cause of ovarian cancer. Her $1.3 million, prevention-focused project uses artificial intelligence to simultaneously analyse the data of 273,000 women, to determine the most significant factors in indicating if a woman is likely to develop ovarian cancer. This will be the largest study to date of individual genetic and physical risk factors. This information will allow the team to characterise risk-factor profiles, which could identify women who are at high risk of developing ovarian cancer and prompt screening and early detection.

  • In an earlier project funded by the OCRF, Associate Professor Carlos Salomon and his team at the University of Queensland discovered a novel biomarker that may play a significant role in developing a reliable early detection test. This project received seed funding and support from OCRF in its early stage. The next phase, which has received more than $2 million from the MRFF, will see them further test the biomarker using samples from a major UK study. This will determine the test’s suitability for general population screening. The test is focused on identifying a type of ovarian cancer that has the highest mortality. To acknowledge the support of the OCRF in the initial stages of this research, Associate Professor Salomon named the algorithm (the early detection method) OCRF-7.

Ms Nolan said “The evolution of these MRFF-funded projects demonstrates the importance of long-term, sustained funding and funders, such as the OCRF and its community of donors, who identify research with potential and promise in the early stages.”

Ovarian cancer kills one woman in Australia every eight hours.

“It is the most lethal female cancer yet is critically underfunded. Improvements in survival rates for women with breast cancer – now 91 percent – came from research, early detection tests, public campaigns and advocacy. We should be proud that the Federal Government and Australians were determined to help save lives,” added Ms Nolan.

“Now it’s ovarian cancer’s turn. Women and girls have waited too long.”

Leadership & Management

Leadership Management Qualities - Leaving an inspirational legacy by taking action and making a difference, says Medicines Australia CEO

Leaving an inspirational legacy by taking action and making a difference, Medicines Australia CEO

Health Industry Hub | September 20, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the Pharma, […]


Human Resources

Human Resource Management - Winners revealed at 2021 Australian HR Awards; Johnson & Johnson the only healthcare company to secure a win

Winners revealed at 2021 Australian HR Awards; Johnson & Johnson the only healthcare company to secure a win

Health Industry Hub | September 20, 2021 |

Human Resources: The annual Australian HR Awards has been recognised as the leading independent awards event in the HR profession […]


News & Trends - Pharmaceuticals

Pharma News - MSD's Keytruda excels in early stage melanoma, reducing cancer recurrence post-surgery

MSD’s Keytruda excels in early stage melanoma, reducing cancer recurrence post-surgery

Health Industry Hub | September 20, 2021 |

Pharma News: Patients with stage IIB and IIC melanoma have a deep or ulcerated primary tumour. These patients occur in […]


News & Trends - Medical Technology

MedTech News - AAOS releases new trends from the hip and knee replacement registry

AAOS releases new trends from the hip and knee replacement registry

Health Industry Hub | September 20, 2021 |

MedTech News: The American Academy of Orthopaedic Surgeons (AAOS) Registry Program announced the availability of the American Joint Replacement Registry Program (AJRR) […]